Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co‐localization of eotaxin mRNA to bronchial epithelial and endothelial cells
- 5 December 1997
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 27 (12) , 3507-3516
- https://doi.org/10.1002/eji.1830271252
Abstract
Eotaxin is a newly discovered C‐C chemokine which preferentially attracts and activates eosinophil leukocytes by acting specifically on its receptor CCR3. The airway inflammation characteristic of asthma is believed to be, at least in part, the result of eosinophil‐dependent tissue injury. This study was designed to determine whether there is increased expression of eotaxin and CCR3 in the bronchial mucosa of asthmatics and whether this is associated with disease severity. The major sources of eotaxin and CCR3 mRNA were determined by co‐localization experiments. Bronchial mucosal biopsy samples were obtained from atopic asthmatics and normal non‐atopic controls. Eotaxin and CCR3 mRNA were identified in tissue sections by in situ hybridization (ISH) using radiolabeled riboprobes and their protein product visualized by immunohistochemistry (IHC). Co‐localization experiments were performed by double ISH/IHC. Eotaxin and CCR3 (mRNA and protein) were significantly elevated in atopic asthmatics compared with normal controls. In the asthmatics there was a highly significant inverse correlation between eotaxin mRNA+ cells and the histamine provocative concentration causing a 20% fall in FEV1 (PC20). Cytokeratin‐positive epithelial cells and CD31+ endothelial cells were the major source of eotaxin mRNA whereas CCR3 co‐localized predominantly to eosinophils. These data are consistent with the hypothesis that damage to the bronchial mucosa in asthma involves secretion of eotaxin by epithelial and endothelial cells resulting in eosinophil infiltration mediated via CCR3. Since selective (eotaxin) and non‐selective C‐C chemokines such as RANTES, MCP‐3 and MCP‐4 all stimulate eosinophils via CCR3, this receptor is potentially a prime therapeutic target in the spectrum of diseases involving eosinophil‐mediated tissue damage.Keywords
This publication has 41 references indexed in Scilit:
- Eotaxin Is a Potent Chemotaxin for Human BasophilsBiochemical and Biophysical Research Communications, 1997
- The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment.The Journal of Experimental Medicine, 1995
- Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig LungsBiochemical and Biophysical Research Communications, 1994
- Human Monocyte Chemotactic Proteins-2 and -3 (MCP-2 and MCP-3) Attract Human Eosinophils and Desensitize the Chemotactic Responses Towards RANTESBiochemical and Biophysical Research Communications, 1994
- CC chemokines in allergic inflammationImmunology Today, 1994
- Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine.The Journal of Experimental Medicine, 1994
- The Chemokine, Eotaxin, Activates Guinea-Pig Eosinophils in Vitro and Causes Their Accumulation into the Lung in VivoBiochemical and Biophysical Research Communications, 1993
- T cells and eosinophils in the pathogenesis of asthmaImmunology Today, 1992
- Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils.The Journal of Experimental Medicine, 1992
- Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsivenessJournal of Allergy and Clinical Immunology, 1991